The Medicines Company (NASDAQ:MDCO) Weekly Ratings on May 17, 2018

May 17, 2018 - By Elizabeth Bryant

The Medicines Company (NASDAQ:MDCO) Corporate Logo
Big Money Sentiment increased to 1.25 in 2017 Q4. It has change of 0.47, from 2017Q3’s 0.78. The ratio increased due to The Medicines Company positioning: 26 sold and 51 reduced. 28 funds bought holdings and 68 increased holdings. Investors holded 85.15 million in 2017Q3 but now own 89.44 million shares or 5.03% more.
Teachers Retirement System Of The State Of Kentucky reported 0.01% in The Medicines Company (NASDAQ:MDCO). Hall Laurie J Trustee owns 0.01% invested in The Medicines Company (NASDAQ:MDCO) for 790 shs. Amalgamated Bancorporation has 10,022 shs for 0.01% of their capital. Corvex Limited Partnership invested in 3.16% or 2.41 million shs. Gemmer Asset Limited Liability holds 92 shs. Raymond James And Associate accumulated 10,957 shs. Greenlight has invested 0.5% in The Medicines Company (NASDAQ:MDCO). Parallax Volatility Advisers L P holds 10,500 shs. Gp One Trading Limited Partnership stated it has 0.01% in The Medicines Company (NASDAQ:MDCO). Goldman Sachs Group holds 985,804 shs or 0.01% of its capital. Louisiana State Employees Retirement Sys holds 0.03% in The Medicines Company (NASDAQ:MDCO) or 27,600 shs. State Board Of Administration Of Florida Retirement stated it has 40,429 shs. Point72 Asset Management L P invested in 0% or 35,235 shs. Pnc Financial Serv Gru reported 0% stake. New York State Teachers Retirement Sys accumulated 147,007 shs.

The Medicines Company registered $783,400 net activity with 1 insider buy and 3 insider sales since December 7, 2017. $241,950 worth of The Medicines Company (NASDAQ:MDCO) was sold by CROUSE WILLIAM. $574,200 worth of The Medicines Company (NASDAQ:MDCO) shs were sold by KESSLER ARMIN M. Shares for $3.71 million were sold by MEANWELL CLIVE on Friday, December 15.

The Medicines Company (NASDAQ:MDCO) Ratings Coverage

In total 3 analysts cover Medicines Co (NASDAQ:MDCO). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 6 are the (NASDAQ:MDCO)’s analyst reports since November 29, 2017 according to StockzIntelligence Inc. On Wednesday, November 29 the company was upgraded by Oppenheimer. In Thursday, February 22 report Oppenheimer maintained the stock with “Hold” rating. In Thursday, March 22 report Oppenheimer maintained the stock with “Buy” rating. On Monday, January 15 the firm earned “Buy” rating by Oppenheimer. On Monday, January 22 the firm earned “Buy” rating by Citigroup. Listed here are The Medicines Company (NASDAQ:MDCO) PTs and latest ratings.

22/03/2018 Broker: Oppenheimer Rating: Buy Maintain
22/02/2018 Broker: Oppenheimer Rating: Hold New Target: $50.0 Maintain
24/01/2018 Broker: J.P. Morgan Rating: Buy New Target: $45.0
22/01/2018 Broker: Citigroup Rating: Buy New Target: $40.0 Upgrade
15/01/2018 Broker: Oppenheimer Rating: Buy New Target: $50.0 Maintain
29/11/2017 Broker: Oppenheimer Rating: Buy New Target: $50.0 Upgrade

MDCO is reaching $32.2 during the last trading session, after increased 0.22%.The Medicines Company has volume of 288,319 shares. Since May 17, 2017 MDCO has declined 34.73% and is downtrending. MDCO underperformed by 46.28% the S&P 500.

The Medicines Company, a biopharmaceutical company, provides medicines for patients in acute and intensive care hospitals worldwide.The firm is worth $2.37 billion. The firm markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention; Ionsys, a fentanyl iontophoretic transdermal system for the short term management of acute postoperative pain for adults requiring opioid analgesia in the hospital.Currently it has negative earnings. It also markets Minocin IV, an intravenous formulation of a tetracycline-class antibiotic used for the treatment of infections due to susceptible strains of designated gram-negative bacteria; and Orbactiv, an intravenous antibiotic used for the treatment of adult patients with acute bacterial skin and skin structure infections, or caused or suspected to be caused by susceptible isolates of designated gram-positive microorganisms.

For more The Medicines Company (NASDAQ:MDCO) news published recently go to: Fool.com, Streetinsider.com, Seekingalpha.com, Streetinsider.com or Fool.com. The titles are as follows: “Alnylam Looks Forward” published on May 08, 2018, “Einhorn’s Greenlight Capital Enters Office Depot (ODP), Abercrombie & Fitch (ANF) (more…) – 13F” on May 15, 2018, “The Medicines (MDCO) Q1 2018 Results – Earnings Call Transcript” with a publish date: April 25, 2018, “Medicines Co. (MDCO) ORION-1 Phase II Study Shows Significant Reductions in Potentially Harmful Subtypes of Bad …” and the last “Is Alnylam Pharmaceuticals, Inc. (ALNY) a Buy?” with publication date: May 17, 2018.

The Medicines Company (NASDAQ:MDCO) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.